Financial Partners Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Financial Partners Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$293K	–	112
2020 Q4	$293K	Hold	4,000	–	–	0.07%	90
2020 Q3	$311K	Buy	+4,000	New	+$275K	0.08%	86

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Financial Partners Capital Management's HZNP Position: Q1 2021 in Review

Financial Partners Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 4,000 shares — an estimated $293K sold.

Financial Partners Capital Management first reported a position in HZNP in Q3 2020 and held it in 2 quarters. The position peaked at $311K in Q3 2020. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

Financial Partners Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
Financial Partners Capital Management sold 4,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $293K.
Financial Partners Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 2 quarters.
Financial Partners Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $311K in Q3 2020.
516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Financial Partners Capital Management's 13F filing for Q1 2021, filed 27 Feb 2023.